HuGE Literature Finder
Records
1
-
10
| Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels. Annals of hematology 2022 Oct . Lewandowski Krzysztof, Kandu?a Zuzanna, Gniot Micha?, Paczkowska Edyta, Nawrocka Paulina Maria, Wojtaszewska Marzena, Janowski Micha?, Mariak Magdalena, Handschuh Luiza, Kozlowski Pio |
| Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia 2020 6 35 (2): 468-475. Barosi Giovanni, Rosti Vittorio, Catarsi Paolo, Villani Laura, Abbà Carlotta, Carolei Adriana, Magrini Umberto, Gale Robert Peter, Massa Margherita, Campanelli Ri |
| Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. Medical oncology (Northwood, London, England) 2018 Aug 35 (9): 119. Helbig Grzego |
| Racial Disparities in the Molecular Landscape of Cancer. Anticancer research 2018 04 38 (4): 2235-2240. Heath Elisabeth I, Lynce Filipa, Xiu Joanne, Ellerbrock Angela, Reddy Sandeep K, Obeid Elias, Liu Stephen V, Bollig-Fischer Aliccia, Separovic Duska, Vanderwalde A |
| Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. British journal of haematology 2016 Jun . Beauverd Yan, Alimam Samah, McLornan Donal P, Radia Deepti H, Harrison Claire |
| Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia 2015 Jun 29 (6): 1344-9. Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli |
| Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014 Dec 28 (12): 2300-3. Tefferi A, Wassie E A, Lasho T L, Finke C, Belachew A A, Ketterling R P, Hanson C A, Pardanani A, Gangat N, Wolanskyj A |
| Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014 Oct 124 (16): 2507-13; quiz 2615. Tefferi Ayalew, Guglielmelli Paola, Larson Dirk R, Finke Christy, Wassie Emnet A, Pieri Lisa, Gangat Naseema, Fjerza Rajmonda, Belachew Alem A, Lasho Terra L, Ketterling Rhett P, Hanson Curtis A, Rambaldi Alessandro, Finazzi Guido, Thiele Juergen, Barbui Tiziano, Pardanani Animesh, Vannucchi Alessandro |
| Mutations and prognosis in primary myelofibrosis. Leukemia 2013 Sep 27 (9): 1861-9. Vannucchi A M, Lasho T L, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling R P, Rotunno G, Knudson R A, Susini M C, Laborde R R, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross N C P, Tefferi |
| JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008 Jan 93 (1): 34-40. Schmitt-Graeff Annette H, Teo Soon-Siong, Olschewski Manfred, Schaub Franz, Haxelmans Sabine, Kirn Andreas, Reinecke Petra, Germing Ulrich, Skoda Radek |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: